Fc&ggr;RIIa and Fc&ggr;RIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome
暂无分享,去创建一个
M. Economou | A. Tragiannidis | F. Athanassiadou-Piperopoulou | N. Vavatsi-Christaki | Andromachi Papagianni | N. Gombakis | Fekri Samarah | E. Karatza | M. Athanassiou-metaxa
[1] Drew Provan,et al. International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.
[2] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[3] A. Lazarus,et al. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. , 2003, Journal of pediatric hematology/oncology.
[4] R. Westendorp,et al. Evidence for non-random distribution of Fcγ receptor genotype combinations , 2003, Immunogenetics.
[5] J. Freedman,et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. , 2003, Blood.
[6] R. Geha,et al. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. , 2003, The Journal of allergy and clinical immunology.
[7] R. Geha,et al. Desloratadine inhibit T-cell responses, airway inflamation, and bronchial hyperresponsiveness (BHR) in murine models of asthma , 2003 .
[8] V. Blanchette,et al. Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura , 2003 .
[9] G. Buchanan,et al. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. , 2002, The Journal of pediatrics.
[10] T. Shimomura,et al. Involvement of Fcγ receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura , 2001 .
[11] C. Hack,et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. , 2001, Blood.
[12] S. Steinberg,et al. Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study , 2001, British journal of haematology.
[13] J. G. Winkel,et al. IgG receptor polymorphisms: risk factors for disease , 1998, Immunogenetics.
[14] R. Kimberly,et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. , 1997, The Journal of clinical investigation.
[15] D. Roos,et al. FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .
[16] M. Fanger,et al. Monoclonal antibody 197 (anti‐FcγRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down‐modulation of FcγRI on circulating monocytes , 1996 .
[17] P. Parren,et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. , 1992, The Journal of clinical investigation.
[18] J. V. D. van de Winkel,et al. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. , 1991, Journal of immunology.
[19] J. Hall,et al. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. , 1986, The Journal of clinical investigation.
[20] R. Kimberly,et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody , 1986 .
[21] V. Blanchette,et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. , 2003, British journal of haematology.
[22] R. Westendorp,et al. Evidence for non-random distribution of Fcgamma receptor genotype combinations. , 2003, Immunogenetics.
[23] J. V. Ravetch,et al. IgG Fc receptors. , 2001, Annual review of immunology.
[24] T. Shimomura,et al. Involvement of Fc gamma receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. , 2001, British journal of haematology.
[25] J. V. D. van de Winkel,et al. IgG receptor polymorphisms: risk factors for disease , 1998, Immunogenetics.
[26] D. Roos,et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.
[27] M. Poncz,et al. Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). , 1996, Journal of immunological methods.
[28] M. Fanger,et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. , 1996, British Journal of Haematology.
[29] M. Poncz,et al. Rapid detection of the ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED) , 1996 .
[30] R. Kimberly,et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. , 1986, The New England journal of medicine.